Kara N. Maxwell, MD, PHD

Valle LF, Scobie M, Rowe K, Pritchard CC, Montgomery B, Garraway IP, Nickols NG, Schoen MW, Kishan AU, Kelley MJ, Rettig MB, Maxwell KN. Interference of Clonal Hematopoiesis in cfDNA Liquid Biopsy Testing & Identification of Actionable Alterations in Large Diverse Cohort of US Veterans , Oncologist, oyag265: 2026

Buckley KH, Dungan ME, Dinh K, Kelly GM, Hausler R, Bennett KE, Clay DG, Youngman JE, Majer AD, Beyries KA, Niccum BA, Shaffer SM, Karakasheva TA, Hamilton KE, Kochman ML, Ginsberg GG, Ahmad N, Maxwell KN, Katona BW Gastric epithelium from BRCA1 and BRCA2 carriers harbors increased double-stranded DNA damage and augmented growth , Mol Cancer Res, 24(7): 2026,589-600

Schoen MW, Li J, Zeng S, Desai H, Hausler R, Haroldsen CL, Owens L, Valle LF, Etzoni RB, Rebbeck TR, Rose BS, Kelley MJ, Montgomery RB, Nickols NG, Rettig MB, Yamoah K, Maxwell KN, Garraway IP. Genomic Classification to Predict Survival in Metastatic Prostate Cancer: Development of Somatic Tumor Risk Assessment for Overall Survival-Prostate , JCO Precis Oncol, 10(7): 2026,e2600021

Crawford TB, Tayeb M, Barrett E, Al-Saleem T, Kondam P, Hausler R, Symecko H, Orr C, Wolfe C, Mann D, Spielman K, Wong G, Haas N, Narayan V, Robinson K, Takvorian S, Wong YN, Sokolova A, Montgomery RB, Menendez C, Kelley MJ, Aiello LB, Garraway IP, Domchek SM, Maxwell KN Pathogenic germline variants in a racially diverse real-world cohort of prostate cancer patients , J Natl Compr Canc Netw, 24(7): 2026,e267006

Pepin A, Doucette A, Narayan VK, Maxwell KN, Takvorian SU, O'Brien SR, Mankoff DA, Mulugeta PG, Taunk NK. Differential Response to (177)Lu-PSMA-617 in Patients with Tumor Suppressor Gene-Mutated Metastatic Castration-Resistant Prostate Cancer , J Nucl Med, 67(6): 2026,926-928

MacFarland SP, Goodman VE, King-Dowling S, Zelley K, Crompton BD, Schultz KAP, Maese LD, Maxwell KN, Khincha PP, Schwartz LA. Liquid Biopsy for Cancer Screening in Li-Fraumeni Syndrome: Interest in Clinical Trial and Reported Barriers to Standard-of-Care Screening , Cancer Prev Res, 19(6): 2026,331-337

Cheng HH, Maxwell KN, Salari K, Cooperberg MR, Follmer K, Jeter JM, Jun G, Lee DJ, Patel HD, Schaeffer EM, Sokolova AO, Wolff EM, Lin DW. The 'Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease' (PATROL) study , BJU Int: 2026

Moses R, Powers J, Levine AS, Garber JE, MacFarland SP, Rana HQ, Murphy ME, Maxwell KN. The biology of hypomorphic TP53 variants and implications for clinical management , Clin Cancer Res: 2026

Buckley KH, Zhu Y, Dinh K, Hausler R, Gala R, Spiegel SR, Delgado R, Clay DG, Kelly GM, Brower J, Domchek SM, Maxwell KN, Katona BW. Prevalence of Helicobacter pylori Exposure and Risk Factors Among BRCA1 and BRCA2 Carriers , Int J Cancer: 2026

Xu G, Karunamuni R, Dornisch AM, Brunette CA, Danowski ME, Desai H, Dochtermann D, Garraway IP, Hauger RL, Kibel AS, Lynch JA, Pyarajan S, Rose BS, Teerlink CC, Andreassen OA, Dale AM, Donovan JL, Hamdy F, Kachuri L, Lane A, Martin RM, Mills IG, Neal DE, Turner EL, Witte JS, Schleutker J, Pashayan N, Batra J; Australian Prostate Cancer BioResource (APCB); Nordestgaard BG, Hamilton RJ, Wolk A, Albanes D, Atkins J, Blot WJ, Mucci LA, Nielsen SF, Cussenot O, Berndt SI, Koutros S, Sørensen KD, Cybulski C, Menegaux F, Park JY, MacInnis RJ, Rosenstein BS, Lu YJ, Watya S, Vega A; NC-LA PCaP Investigators; IMPACT Study Steering Committee and Collaborators; Kogevinas M, Wiklund F, Plym A, Teixeira MR, Multigner L, Leach RJ, Brenner H, John EM, Kaneva R, Logothetis CJ, Neuhausen SL, Ost P, Razack A, Fowke JH, Gamulin M, Usmani N, Claessens F, Castelao JE, Petrovics G, Parent MÉ, Hu JJ, Zheng W; Profile Study Steering Committee; UKGPCS collaborators; Kote-Jarai Z, Eeles RA; PRACTICAL Consortium; VA Million Veteran Program; Maxwell KN, Vassy JL, Seibert TM. Germline polygenic score for prostate cancer aggressiveness , medRxiv: 2026,2026.05.07.26352488